GLYCOSELECT LIMITED

GlycoSeLect Ltd is a specialist life‑science company that designs and manufactures recombinant prokaryotic lectins (RPLs). These engineered, glycoselective bio‑affinity proteins enable rapid, highly specific detection, analysis and isolation of glycosylated biomolecules, offering clear advantages over conventional analytical and purification techniques.

The core offering centres on the production of scalable RPLs that can be deployed from small‑scale analytical assays right through to full‑scale manufacturing processes. By providing a robust, reproducible alternative to traditional lectin‑based methods, GlycoSeLect serves researchers, biopharmaceutical developers and analytical laboratories seeking more efficient ways to characterise and purify glycoproteins. The company also makes peer‑reviewed research on its products readily available, underscoring its commitment to scientific rigour and transparency.

Through ongoing innovation—highlighted in recent news such as the application of RPLs to SARS‑CoV‑2 antibody testing—GlycoSeLect continues to expand the toolkit available to the life‑science sector, helping clients accelerate discovery and production with confidence.